Summit Therapeutics Statistics
Share Statistics
Summit Therapeutics has 737.68M
shares outstanding. The number of shares has increased by 5.08%
in one year.
Shares Outstanding | 737.68M |
Shares Change (YoY) | 5.08% |
Shares Change (QoQ) | 0.07% |
Owned by Institutions (%) | 12.74% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 37,550 |
FTD / Avg. Volume | 0.94% |
Short Selling Information
The latest short interest is 25.09M, so 3.4% of the outstanding
shares have been sold short.
Short Interest | 25.09M |
Short % of Shares Out | 3.4% |
Short % of Float | 21.08% |
Short Ratio (days to cover) | 5.06 |
Valuation Ratios
The PE ratio is -57.95 and the forward
PE ratio is -57.14.
Summit Therapeutics's PEG ratio is
0.84.
PE Ratio | -57.95 |
Forward PE | -57.14 |
PS Ratio | 0 |
Forward PS | 9.4 |
PB Ratio | 32.99 |
P/FCF Ratio | -90.17 |
PEG Ratio | 0.84 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Summit Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.15,
with a Debt / Equity ratio of 0.02.
Current Ratio | 10.15 |
Quick Ratio | 10.15 |
Debt / Equity | 0.02 |
Debt / EBITDA | -0.03 |
Debt / FCF | -0.05 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | $-1,391,918.24 |
Employee Count | 159 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 357.25% in the
last 52 weeks. The beta is -0.46, so Summit Therapeutics's
price volatility has been lower than the market average.
Beta | -0.46 |
52-Week Price Change | 357.25% |
50-Day Moving Average | 21.58 |
200-Day Moving Average | 19.12 |
Relative Strength Index (RSI) | 49.97 |
Average Volume (20 Days) | 4,001,020 |
Income Statement
Revenue | n/a |
Gross Profit | -15.01M |
Operating Income | 313K |
Net Income | -221.31M |
EBITDA | -212.85M |
EBIT | -230M |
Earnings Per Share (EPS) | -0.31 |
Full Income Statement Balance Sheet
The company has 104.86M in cash and 7.22M in
debt, giving a net cash position of 97.64M.
Cash & Cash Equivalents | 104.86M |
Total Debt | 7.22M |
Net Cash | 97.64M |
Retained Earnings | -1.21B |
Total Assets | 383.82M |
Working Capital | 335.87M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -142.11M
and capital expenditures -139K, giving a free cash flow of -142.25M.
Operating Cash Flow | -142.11M |
Capital Expenditures | -139K |
Free Cash Flow | -142.25M |
FCF Per Share | -0.2 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |